ARWR insider transaction filings
ARROWHEAD PHARMACEUTICALS, INC. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen ARWR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | OLUKOTUN ADEOYE Y — Director | Sale (S): 2,000 @ $86.96 | EDGAR |
| 2026-08-20 | 4 | PERRY MICHAEL S — Director | Sale (S): 11,600 @ $87.30 | EDGAR |
| 2026-06-17 | 4 | Cohen Matthew Gregory — Director | Grant/award (A): 11,882 @ $0 | EDGAR |
| 2026-05-14 | 4 | Lu Hongbo — Director | Sale (S): 2,970 @ $76.88 | EDGAR |
| 2026-04-24 | 4 | Apel Daniel Joseph — Chief Financial Officer | Sale (S): 3,208 @ $70.11 · Sale (S): 1,157 @ $70.45 · Sale (S): 8,730 @ $71.92 | EDGAR |
| 2026-04-24 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 10,000 @ $75 | EDGAR |
| 2026-03-09 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 10,000 @ $64.19 | EDGAR |
| 2026-01-08 | 4 | Apel Daniel Joseph — Chief Financial Officer | Grant/award (A): 75,000 @ $0 | EDGAR |
| 2026-01-08 | 4 | Hamilton James C — Chief Medical Officer | Grant/award (A): 75,000 @ $0 | EDGAR |
| 2026-01-08 | 4 | O'Brien Patrick — COO | Gift (G): 540 @ $0 · Gift (G): 540 @ $0 · Gift (G): 540 @ $0 · Gift (G): 440 @ $0 · Gift (G): 440 @ $0 · Grant/award (A): 75,000 @ $0 | EDGAR |
| 2026-01-05 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 4,625 @ $61.24 · Sale (S): 6,090 @ $62.28 · Sale (S): 14,792 @ $63.01 · Sale (S): 12,711 @ $63.95 · Sale (S): 1,200 @ $64.49 · Sale (S): 437 @ $65.97 · +1 more | EDGAR |
| 2026-01-05 | 4 | O'Brien Patrick — COO | Gift (G): 560 @ $0 · Gift (G): 560 @ $0 · Gift (G): 560 @ $0 · Gift (G): 560 @ $0 · Gift (G): 560 @ $0 · Sale (S): 4,368 @ $61.20 · +11 more | EDGAR |
| 2026-01-05 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Sale (S): 7,416 @ $65.88 · Sale (S): 5,771 @ $66.39 | EDGAR |
| 2025-12-30 | 4 | Ferrari Mauro — Director | Sale (S): 7,530 @ $70 | EDGAR |
| 2025-12-30 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Option exercise (M): 35,181 @ $6.15 · Option exercise (M): 16,545 @ $6.15 · Sale (S): 35,181 @ $69.33 · Sale (S): 16,545 @ $68.69 · Option exercise (M): 35,181 (derivative) @ $0 · Option exercise (M): 16,545 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Vakiener Victoria — Director | Sale (S): 2,799 @ $66.63 · Sale (S): 5,281 @ $67.97 · Sale (S): 1,960 @ $68.39 | EDGAR |
| 2025-12-23 | 4 | Waddill William D. — Director | Sale (S): 2,416 @ $66.66 · Sale (S): 5,451 @ $68.01 · Sale (S): 500 @ $68.53 | EDGAR |
| 2025-12-23 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Sale (S): 3,979 @ $66.67 · Sale (S): 8,147 @ $68.01 · Sale (S): 1,319 @ $68.48 · Sale (S): 10,012 @ $68.33 · Sale (S): 2,574 @ $68.85 | EDGAR |
| 2025-12-23 | 4 | OLUKOTUN ADEOYE Y — Director | Sale (S): 3,090 @ $66.70 · Sale (S): 6,083 @ $68.04 · Sale (S): 827 @ $68.48 | EDGAR |
| 2025-12-19 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Sale (S): 46,287 @ $63.55 · Sale (S): 35,750 @ $64.51 · Sale (S): 982 @ $65.53 · Sale (S): 1,981 @ $66.30 | EDGAR |
| 2025-12-18 | 4 | Vakiener Victoria — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | Lu Hongbo — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | Waddill William D. — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | Ferrari Mauro — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | PERRY MICHAEL S — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | OLUKOTUN ADEOYE Y — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-18 | 4 | INGRAM DOUGLAS S — Director | Grant/award (A): 7,819 @ $0 | EDGAR |
| 2025-12-16 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Grant/award (A): 180,000 @ $0 · Sale (S): 100,532 @ $68.67 · Sale (S): 21,321 @ $69.28 · Sale (S): 8,147 @ $69.96 · Sale (S): 8,416 @ $60.51 · Sale (S): 10,963 @ $61.25 · +7 more | EDGAR |
| 2025-12-09 | 4 | PERRY MICHAEL S — Director | Sale (S): 16,250 @ $61.03 | EDGAR |
| 2025-12-01 | 4 | Ferrari Mauro — Director | Sale (S): 8,750 @ $56.39 | EDGAR |
| 2025-10-03 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 20,000 @ $35 | EDGAR |
| 2025-09-16 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 15,000 @ $30 | EDGAR |
| 2025-09-04 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 15,000 @ $25 | EDGAR |
| 2025-08-15 | 4 | Hamilton James C — Chief Medical Officer | Sale (S): 611 @ $20 · Sale (S): 9,389 @ $20 | EDGAR |
| 2025-04-11 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Sale (S): 35,305 @ $9.93 · Sale (S): 3,400 @ $10.75 · Sale (S): 1,617 @ $11.76 · Sale (S): 50,000 @ $10.87 · Sale (S): 50,800 @ $11.49 | EDGAR |
| 2025-03-17 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Grant/award (A): 340,000 @ $0 · Sale (S): 51,425 @ $15.07 | EDGAR |
| 2025-03-05 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Option exercise (M): 166,667 @ $7.75 · Option exercise (M): 133,333 @ $7.75 · Sale (S): 166,667 @ $18.03 · Sale (S): 133,333 @ $17.02 · Option exercise (M): 166,667 (derivative) @ $0 · Option exercise (M): 133,333 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Anzalone Christopher Richard — Chief Executive Officer, Director | Grant/award (A): 9,550 @ $20.10 | EDGAR |
| 2025-02-07 | 4 | INGRAM DOUGLAS S — Director | Grant/award (A): 38,396 @ $20.09 | EDGAR |
Recent 8-K events — ARROWHEAD PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARWR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →